Introduction
Nowadays, the incidence of invasive fungal infection is increasing year by year with the continuous development of organ transplantation, interventional therapy and the widespread use of broad-spectrum antibiotics, glucocorticoids and immunosuppressants (Kriengkauykiat et al. 2011) . There are only a few antifungal agents available, such as azoles, polyenes, echinocandins and allylamines (Cui et al. 2015) . With the widespread use of these antifungals, especially azoles, fungal drug resistance is more and more common (Cowen and Steinbach 2008) . In addition, the adverse effects or toxicities of the available antifungal agents has also limited their use in clinical practice (Campoy and Adrio 2017) . These problems pose a great challenge in the clinical treatment of invasive fungal infections. Thus, discovering new antifungal agents or overcoming drug resistance has become a hot topic in the antifungal field. However, the development of new antifungals requires huge capital investment, a powerful research team and a long time to complete. Research into the antifungal effects of existing clinical drugs is one solution to overcome the current challenges (Pierce and Lopez-Ribot 2013) .
Recently, many studies have found that some non-antifungal agents displayed antifungal activity, especially in combination with azoles. Immunosuppressive agents are a class of drugs having inhibitory effects on the immune response, and are mainly used in preventing and treating organ transplant rejection and autoimmune disease. Although using immunosuppressive agents could lead to a reduction of immune function and there is a risk of causing fungal infection, research on the antifungal activities of immunosuppressive agents has still been carried out in recent years. The results showed that several immunosuppressive agents have antifungal properties when used alone or in combination with antifungals, including calcineurin (CN) inhibitor, anti-metabolic agent, target of rapamycin (TOR) inhibitor, traditional Chinese medicine and glucocorticoid. The major antifungal mechanisms are related to inhibition of downstream targets of the calcium-CN signalling pathway and the PI3K-AKT-TOR signalling pathway, as well as inhibition of drug efflux. The value of this research and its applications need further discussion. In this paper, research on the antifungal activity of immunosuppressants used alone or in combination and potential antifungal mechanisms are reviewed. The key results on the interaction of immunosuppressants in combination with fluconazole (FLC) are summarized in Table 1 . Although these drugs could not be used as antifungal agents in clinical practice at present, we believe these findings are valuable. The study of their analogues with low immunosuppressive activity may be a direction to discovering new antifungal agents. Furthermore, findings on the mechanism would provide deep insight into overcoming antifungal resistance.
The antifungal activity of calcineurin inhibitor
Calcium, the second messenger, is essential for numerous physiological processes in eukaryotic cells. Calcium homeostasis and its signalling systems play an important role in cell survival during exposure to a variety of environmental stresses. Calcineurin, directly regulated by Ca 2+ , is a conserved serine-threonine-specific protein phosphatase in the eukaryote calcium-CN signalling network. Calcineurin plays an important role in calcium signalling, which is considered to be a common target of CN inhibitors, such as cyclosporine A (CsA), tacrolimus and pimecrolimus. Moreover, their immunosuppressive mechanisms occur by inhibiting the activity of CN, regulating its downstream transcription factor NFAT (nuclear factor of activated T cells), eventually affecting T-cell activation and IL-2 secretion (Fig. 1) .
Recently, many researchers have reported that CN was involved in hyphal growth, virulence and drug resistance in diverse fungi. Chen et al. (2014) showed that Candida tropicalis could form hyphae and pseudohyphae on cornmeal solid agar medium. Calcineurin mutated strains attenuated the growth of hyphae, mainly in the form of yeast and pseudohyphae, demonstrating that CN is essential for the hyphal growth of C. tropicalis. In addition, several studies have reported that CN was also involved in the hyphal growth of Candida dubliniensis (Chen et al. 2011) , Aspergillus fumigatus (Steinbach et al. 2006) and Cryptococcus neoformans (Cruz et al. 2001a) . It was also found that a CN mutant showed a significant decrease in virulence when compared with C. tropicalis wild-type strain. In the murine systemic infection model, the mortality of mice caused by C. tropicalis wild-type strain was 100% at 10 days; whereas the CN mutant only resulted in 10% mortality even after 42 days . The data suggested that CN regulated the virulence of fungi. Echinocandin-and azole-resistant C. tropicalis were frequently isolated from various patients around the world (Yang et al. 2012; Jensen et al. 2013) . Chen et al. (2014) confirmed that C. tropicalis CN mutants were susceptible to echinocandins and azoles, and considered that CN was related to drug resistance. Calcineurin was also associated with the drug resistance of C. dubliniensis, Candida albicans and Candida glabrata to echinocandins and azoles (Cruz et al. 2002; Chen et al. 2011 Chen et al. , 2012 . Moreover, it was also reported that a CN inhibitor, FK506, combined with caspofungin showed a synergistic fungicidal activity against echinocandin-resistant C. dubliniensis; meanwhile, it also exhibited synergistic antifungal activity with azoles against azole-resistant C. albicans Zhang et al. 2012) . These reports demonstrated that CN regulated the drug resistance of Candida species.
Azole antifungal agents are considered to be first-line therapeutic drugs for fungal infections because of their effective antifungal activity and good safety profile (Hashemi et al. 2015; Nabili et al. 2016) . However, the long-term use of azoles has resulted in the emergence of resistant strains. Numerous studies have demonstrated that CN inhibitors such as CsA, tacrolimus and pimecrolimus exhibited obvious synergistic or additive effects when combined with azole agents, including FLC, itraconazole (ITC) and voriconazole (VRC) against resistant fungi.
Cyclosporine A
Cyclosporine A (CsA), a natural product of soil fungi, exhibited significant synergistic effects with FLC against several fungi, including C. albicans, C. orthopsilosis and Talaromyces (Penicillium) marneffei. Candida albicans is the most common pathogen of Candida spp. with strong virulence (Sampath et al. 2017) . Wibawa et al. (2015) found that CsA alone had no antifungal activity in vitro against both FLC-resistant and FLC-sensitive C. albicans, but when combined with FLC there was a significant decrease in the MIC of FLC against both FLC-resistant and FLC-sensitive C. albicans (P < 0Á001). Moreover, Marchetti et al. (2000b) reported that the MIC 100 of CsA and FLC tested alone against C. albicans CAF2-1 were >10 and >32 lg ml À1 , respectively, and decreased to 0Á625 and 0Á5 lg ml À1 when the two drugs were combined in a checkerboard microtitre plate testing, showing promising synergistic effects (FICI was 0Á0785). These results suggest that CsA might be a promising sensitizer for FLC against C. albicans. The interaction between CsA and three azoles (FLC, ITR and VRC) against azole-susceptible/resistant C. albicans was also studied by the chequerboard method in vitro . The results showed that CsA displayed potent synergism against C. albicans when combined with the azoles, especially the azole-resistant strains (Table 1) . A potent synergistic activity has also been reported between CsA and FLC against a standard strain of C. albicans ATCC 90028 and C. orthopsilosis by the microdilution method, FICI were all <0Á5 (Shinde et al. 2012; Cordeiro Rde et al. 2014) . Moreover, the synergistic effects between CN inhibitors (CsA and FK506) and FLC were observed against six Saccharomyces cerevisiae and six C. glabrata strains by the checkerboard microdilution assay. The results showed that the combination of FLC and CsA exhibited a synergistic effect against two S. cerevisiae and five C. glabrata strains, while the combination of FLC and FK506 displayed synergism against all strains of S. cerevisiae and C. glabrata (Tome et al. 2018) .
Notably, the combination of CsA with FLC also exhibited a synergistic effect on C. albicans biofilm formation, with a FICI of 0Á26 (Shinde et al. 2012) . Morphological analysis using fluorescent microscopy further revealed that CsA (75 lg ml
À1
) combined with FLC (32 lg ml
) could inhibit C. albicans cell growth and hyphal formation over 4, 24 and 48 h (Jia et al. 2016) . In recent years, studies have found that biofilm formation is one of the causes of fungal resistance. Their synergistic anti-biofilm effects provide new hope for overcoming fungal resistance.
The synergistic antifungal effect of CsA and FLC was also studied in rats with C. albicans experimental endocarditis (Marchetti et al. 2000a) . Rats were treated with FLC, CsA and FLC-CsA for 5 days. The results revealed that untreated rats showed massive pseudohyphae growth, while only the combination of CsA with FLC significantly reduced the fungal densities compared with other groups in the growth (P < 0Á0001). The synergistic antifungal effect of CsA and FLC was confirmed in vivo. In another study, the synergy between CsA and FLC was also explored in a C. albicans murine keratitis model (Onyewu et al. 2006) . There was no significant difference after treatment between untreated and CsA-treated mice (P > 0Á2). However, CsA-FLC combination therapy improved mice corneal infection more rapidly than with FLC-therapy. These results indicated that CsA combined with FLC exhibited a significant synergistic antifungal effect on infected animals.
Tacrolimus
Tacrolimus, also known as FK506, is a fermentation product separated from Streptomyces tsukubaensis. Many studies have demonstrated that FK506 not only exerted immunosuppressive properties but also displayed significant synergistic effects when combined with azoles against Candida spp. especially the resistant strains. Cruz et al. reported that FK506 in combination with FLC could reverse the drug resistance against FLCresistant C. albicans. The study showed that FK506 combined with FLC displayed significant synergistic effects by the chequerboard microdilution, with the MIC 100 of FLC decreasing from >16 to 0Á5-4 lg ml À1 and FICI were <0Á5 for all the tested strains (Cruz et al. 2002) . The synergistic effects of FK506 and azoles (FLC, ITC and VRC) against azole-susceptible/ resistant C. albicans were also revealed in vitro by the checkerboard microdilution method and the time-killing test . Based on this research, it was revealed that the susceptibility of C. albicans to FLC could be enhanced by FK506, especially against resistant C. albicans in vitro. Furthermore, the impact of the FK506-FLC combination against C. albicans biofilm was also analysed in a rat venous catheter biofilm model by scanning electron microscopy (Uppuluri et al. 2008) . There were significant differences in the FK506-FLC combination group compared with the saline-treated control group and the drug alone group, and the images of the two-drug combination group showed complete inhibition of the biofilm.
In addition to C. albicans, the combination of FLC and FK506 also displayed synergistic effects against non-albicans species. Candida krusei is one of the notorious Candida spp. account for its intrinsic resistance to FLC. Li et al. (2014) demonstrated that FK506 enhanced the susceptibility of C. krusei to FLC and the MIC of FLC was reduced by 4-16-fold, displaying a strong significant synergistic effect (0Á0781 ≤ FICI ≤ 0Á2510). Candida glabrata, followed by C. albicans, was considered to be the second most common human pathogen causing Candida infections (Pfaller and Diekema 2007; Tadec et al. 2016) . Li et al. (2015) evaluated the combined effect of FK506 and FLC against C. glabrata by a chequerboard method. The results showed that FLC in combination with FK506 exerted synergistic effects against C. glabrata at 24/48 h, especially FLC-resistant C. glabrata (Table 1) . These results showed that the combination of FK506 and FLC might be a promising approach to overcoming the intrinsic resistance of non-albicans spp. to FLC.
Malassezia is the most common fungus in mammalian and human skin. Ianiri et al. (2017) (Sugita et al. 2006) . Malassezia spp. are considered to be one of the factors responsible for aggravated atopic dermatitis. Pimecrolimus improves the symptoms of atopic dermatitis attributed not only to its strong antiinflammatory activity but also to the inhibitory effect on the growth of Malassezia species. Pimecrolimus not only displayed anti-Malassezia activity when used alone but also showed an additive effect when combined with FLC. The MIC 80 of pimecrolimus was decreased from >100 to 3Á125 lg ml À1 when FLC was used in combination with pimecrolimus, and the FICI was 0Á531 (Ianiri et al. 2017) . Antifungal mechanisms of immunosuppressants used alone or in combination with antifungals have attracted widespread attention. The common antifungal targets include ergosterol, ergosterol synthase, b(1,3)-D-glucan synthase, chitin synthase, mannan and so on. Recent research showed that CN was also an attractive antifungal target for the development of antifungal agents . Calcineurin consists of a catalytic subunit A (CnA) and a regulatory subunit B (CnB). The antifungal mechanisms of CN inhibitors are described as follows (Fig. 1) . First, CsA, FK506 and pimecrolimus bind the intracellular protein cyclophilin A and FK506-binding protein 12 (FKBP12) (FKBP12 as the common target of FK506 and Pime) respectively to form drug-protein complexes, and then the complexes inhibit the activity of CN via binding the surface between CnA and CnB (Odom et al. 1997; Cruz et al. 2000; Ianiri et al. 2017) . The transcription factor Crz1 is a downstream target of CN in fungi (Karababa et al. 2006) . Crz1 regulates the hyphal growth, virulence and antifungal drug resistance in a CN-dependent or independent manner in diverse yeasts (Steinbach et al. 2007; Chen et al. 2014) .
Inhibition of CN has been established as a potential antifungal target, but efforts to exploit its antifungal properties have always failed due to its associated human immunosuppressive effects. Therefore, studying the correlation of in vitro effects with clinical efficacy is warranted. Moreover, designing less immunosuppressive analogues may contribute to the treatment of invasive fungal infections.
The antifungal activity of anti-metabolic agent
Mycophenolic acid
Mycophenolic acid (MPA) is an inosine monophosphate dehydrogenase (IMPDH) inhibitor, it exerts immunosuppressive effects by specifically inhibiting IMPDH and inhibiting the T and B lymphocyte-dependent de novo biosynthesis of guanosine nucleotides.
It has been reported that MPA exhibited antifungal activity against C. albicans in vitro, with an MIC 50 of 0Á25 lg ml À1 (Kohler et al. 2005) . Several studies have found that MPA combined with antifungals displayed synergistic effects. A recent report suggested that de novo GTP biosynthesis was crucial for the virulence of C. neoformans (Morrow et al. 2012 ). Banerjee et al. found that MPA inhibited the de novo biosynthesis of guanosine and increased the susceptibility of C. neoformans to amphotericin B (AmB). The antifungal activity of AmB was significantly increased when combined with MPA against C. neoformans, with the mean MIC MPA decreased from 30 to 7Á5 lg ml À1 and the mean MIC AmB decreased from 0Á06 to 0Á0075 lg ml À1 . Moreover, the FICI of three independent experiments was ≤0Á5, indicating the synergy between the two drugs. Similarly, the combination of these two drugs also showed synergistic effects against C. albicans, and the mean MIC AmB decreased from 0Á06 to 0Á015 lg ml À1 , suggesting that the antifungal activity of AmB was also enhanced when combined with MPA against C. albicans (Banerjee et al. 2014) . Mycophenolic acid is a commonly used immunosuppressive agent and is widely used in organ transplant patients. It can effectively control the occurrence of organ transplant rejection. Antifungals are often used to prevent fungal infections in immunocompromised populations, including those using MPA. Therefore, the combined use of MPA and antifungals deserves further study.
Mizoribine
Mizoribine (MZP) is another IMPDH inhibitor, and its immunosuppressive mechanism is similar to that of MPA. The antifungal activity of MZP was also observed in vitro, and the MIC 50 of MZP was determined by microdilution assays against three different C. albicans strains and all of these were <0Á4 lg ml À1 (Banerjee et al.
2014).
Inosine monophosphate dehydrogenase derived from wild-type C. albicans is significantly different from human IMPDH (Kohler et al. 2005) , which provides a possibility of selective inhibition of IMPDH inhibitors. These studies indicated that IMPDH was an effective therapeutic target for C. albicans infections. Developing the IMPDH inhibitors or impairing the nucleotide biosynthesis pathway may be an effective strategy for the discovery of antifungals.
The antifungal activity of target of rapamycin inhibitor
The PI3K-AKT-TOR pathway is increasingly recognized as an essential signalling pathway in cells. It is involved in cell proliferation, differentiation and other cellular regulatory functions. TOR as a key downstream of PI3K/ AKT, regulates cell growth, survival and autophagy.
Rapamycin
The first TOR inhibitor rapamycin (Rapa), also known as sirolimus, was initially discovered as an antifungal agent against C. albicans (Vezina et al. 1975) and its immunosuppressive activity was later proved (Martel et al. 1977) . Rapamycin is similar to FK506 in structure, both of which bind to the intracellular receptor FKBP12, but the mechanism of immunosuppression is different (Jain et al. 1993 ). FK506 acts on CN, affecting IL-2 mRNA expression and IL-2 production; whereas rapamycin binds to its specific target TOR via the FKBP12-Rapa complex (Fig. 1) .
In the study of infectious diseases, Galleria mellonella was an ideal infection model of antifungal drug screening and evaluation in vivo because it is easy to operate, susceptible to infection and has other advantages (Junqueira 2012; Li et al. 2013) . A recent study showed that rapamycin increased the survival rate by 50% compared with the 0% survival rate of the PBS control group in a model of G. mellonella infected with Mucor circinelloides (Bastidas et al. 2012 ). In addition, there was no significant difference in the survival rate of uninfected G. mellonella treated with the same dose of rapamycin and PBS, suggesting that the immunosuppressive activity of rapamycin on the survival of G. mellonella was negligible.
The antifungal activity of rapamycin was also studied in a mice infection model. Baker et al. reported that in C. albicans infected mice treated with rapamycin at 20 mg kg
À1
and AmB at 1 mg kg À1 , respectively, the survival rate was approximately the same after 30 days. It was indicated that rapamycin also has good antifungal activity against C. albicans. They also described that 50 and 90% of mice were protected against death from systemic candidosis with an oral administration of 10 and 12Á5 mg kg À1 rapamycin, respectively (Baker et al. 1978) . In addition, rapamycin can significantly improve the survival rate of mice infected with Aspergillus (High and Washburn 1997) . In this study, mice receiving 1 mg kg À1 day À1 rapamycin had a greater survival advantage than those receiving 10 mg kg À1 day
. According to the results, the authors believed that the anti-Aspergillus activity of rapamycin may counteract its immunosuppressive properties in vivo even at high doses. These studies revealed that rapamycin and its analogues have an important prospect as potential antifungal agents.
Moreover, Cruz et al. (2001b) also found that rapamycin exerts antifungal activity against C. albicans, C. neoformans and S. cerevisiae, and its antifungal mechanism is mediated via FKBP12-Rapa inhibition to TOR. TOR is identified as a target of FKBP12-Rapa complexes, and has been found to be highly conserved in yeasts and humans (Alarcon et al. 1996) . It is a member of the phosphoinositide kinase-related kinase family (Fingar and Blenis 2004) , which plays a negative regulatory role in autophagy (Noda and Ohsumi 1998; Huang and Klionsky 2002) . Autophagy is the most basic life phenomenon of eukaryotes, participating in a variety of physiological and pathological processes in the body, such as adaption to hunger and the immune response to microbial infections. Several studies have demonstrated that inhibition of TOR signalling via FKBP12-Rapa could induce autophagy in yeast (Huang and Klionsky 2002; Dibble and Manning 2013; Kim and Guan 2015) . There are two functionally and structurally distinct TOR complexes, TOR complex 1 (TORC1) and TOR complex 2 (TORC2), among which TORC1 is specifically inhibited by rapamycin-FKBP12 complexes directly (Loewith et al. 2002) . TORC1 is composed of TOR1 or TOR2, KOG1, LST8 and Tco89, and is the major autophagy regulator (Kim and Guan 2015; Noda 2017) . The most vital substrates of TORC1 in autophagy are autophagy-related gene 13 (Atg13) and unc-51 like autophagy activating kinase 1 (ULK1) (Noda 2017) . The Atg13 combines with ULK1 and FIP200 to form a stable ULK-Atg13-FIP200 complex, which is the direct target of TORC1 and participates in the regulation of autophagy (Fig. 1) (Jung et al. 2009 ).
Target of rapamycin inhibitors and their less immunosuppressive analogues have attracted much attention due to their antifungal activities, targeting TOR would be a potential strategy for the development of new antifungal agents.
The antifungal activity of traditional Chinese medicine
Traditional Chinese medicine has been used for thousands of years. With improvements in the extraction and separation of chemical composition, the pharmacological studies on effective monomers have increased rapidly. The research found that many traditional Chinese medicines or their extracts not only exhibited immunosuppressive properties, but also displayed obvious antifungal activity.
Tetrandrine
Tetrandrine (TET) is the main effective ingredient of Stephania tetsandran, which is a dibenzylisoquinoline alkaloid extracted from its root. Tetrandine selectively inhibited T cell-dependent immune responses, especially lymphocyte proliferation and differentiation.
Recent studies have shown that TET not only displayed immunomodulatory effects but also exhibited antifungal activity against C. albicans with an MIC 50 value of 32 lg ml À1 in vitro ). In addition, TET increased the sensitivity of C. albicans to FLC. The MIC FLC was reduced from 0Á25 to 0Á0625 lg ml À1 and 64 to 8 lg ml À1 against FLC-susceptible and -resistant C. albicans when combined with 30 lg ml À1 TET by the checkerboard microdilution method, respectively (Guo et al. 2014) . Moreover, TET could obviously improve the survival situation of Caenorhabditis elegans infected with C. albicans . Treatment with TET at concentrations ranging from 4 to 32 mg l À1 resulted in a survival rate of worms that was increased by at least three times after infection for 144 h. Another study reported that TET could enhance the antifungal activity of FLC against C. albicans infection in a disseminated mice model. They found that treatment with 15, 30 and 45 mg kg À1 of TET enhanced the antifungal activities of a subcritical dose (0Á4 or 5 mg kg
À1
) and a minimum dose (0Á8 or 10 mg kg À1 ) of FLC against FLC-sensitive and FLC-resistant C. albicans in infected mice, respectively (Shi et al. 2018) .
Biofilm formation is considered as an important mechanism of antifungal resistance. It has been found that the degree of antifungal resistance is parallel to biofilm formation (Andes et al. 2004) . The resistance of biofilms to common antifungal agents is over 1000 times that of the planktonic cells (Taff et al. 2012) . Zhao et al. investigated the effect of TET on the C. albicans biofilm formation by XTT reduction assay. The result showed that 32 mg l
TET could inhibit biofilm formation significantly (P < 0Á01) . Studying the anti-biofilm mechanisms of TET would contribute to overcoming antifungal drugs resistance.
The polymorphic yeast C. albicans exists in yeast and filamentous forms. Yeast-hyphae transition was considered to be an important virulence factor of C. albicans, especially the colonization and invasion of host tissues (Sudbery et al. 2004; Modrzewska and Kurnatowski 2013) . A study has shown that C. albicans mutants that could not form hyphae exhibited less virulence (Kadosh and Johnson 2005) . Zhao et al. (2013) characterized the inhibitory effect of TET on the hyphal growth of C. albicans, and reported that TET might inhibit hyphal growth via the Ras1p-cAMP-PKA pathway. The yeast-to-hypha transition was an attractive target for the development of new antifungal agents.
In addition, the excessive expression of the drug efflux pump gene MDR1, FLU1, CDR1 and CDR2 was considered to be one reason for azole resistance against C. albicans (Pfaller 2012) . At present, research on the synergistic antifungal mechanism between TET and azoles has also been reported. A recent study indicated that TET could inhibit the expression of MDR1, FLU1, CDR1, CDR2 and reduce drug efflux and increase the accumulation of intracellular azoles, thereby enhancing the sensitivity of C. albicans to FLC (Zhang et al. 2009 (Zhang et al. , 2013a . Zhang et al. (2013b) also found that the synergistic mechanism of FLC and TET against C. albicans was related to inhibition of the drug efflux system by proteomic analysis. In addition to reducing drug efflux and inhibiting biofilm formation, targeting sterol biosynthesis to alter the fluidity and permeability of cell membranes is also one of the antifungal mechanisms of TET (Braga et al. 2007; Ahmad et al. 2010) . Further studies on the underlying mechanisms may help to discover new antifungal agents.
Artemisinin
Artemisinin is a sesquiterpene lactone-containing a peroxide bridge isolated from Artemisia annua L. Research has proved that artemisinin, its derivatives artesunate and artemether have immunosuppressive activities (Noori et al. 2004) . Moreover, the immunosuppressive activities of some acetal-type dihydroartemisinin derivatives are comparable to CsA in vitro (Lee 2007) .
Recently, a number of artemisinin derivatives were screened against C. neoformans to search for effective antifungal agents. The results showed that artemisinin, dihydroartemisinin, arteether and artemether have higher antifungal activities than that of AmB (Lee 2007) . In particular, the antifungal activities of dihydroartemisinin, a-arteether and b-arteether are 4-10 times stronger than that of AmB. However, artemisinin did not exhibit any antifungal activity against C. albicans (Appalasamy et al. 2014) . Appalasamy et al. also studied the toxicity of artemisinin. They found that artemisinin could inhibit the growth of brine shrimp even at the lowest tested concentration (0Á09 mg ml À1 ), and the brine shrimps were all dead within 1 h of incubation, indicating the high toxicity level of artemisinin against the growth of brine shrimps. In addition, a synergistic effect could not be observed between artesunate and FLC, but artesunate could increase the activity of miconazole against C. albicans biofilms (De Cremer et al. 2015) . It has been reported that the tetracyclic trioxane ring system of artemisinin plays a significant role in its antifungal activity (Galal et al. 2005) . Further research on the antifungal mechanism and low-toxic analogues of artemisinin would be a promising strategy for the development of new antifungal agents.
Matrine
Matrine is one of the components of traditional Chinese herb Sophora flavescens. It is a two-way immunomodulator, mainly having an immunosuppressive effect. In a recent study, Wu et al. (2009) examined the effect of matrine against C. albicans biofilms by the XTT reduction assay. The result showed that matrine inhibited the C. albicans biofilms in different growth stages (early, middle, mature). Another study found that matrine could inhibit planktonic cells and biofilms of C. albicans as well as hyphae formation (Shao et al. 2014) . The anti-Candida activity of matrine was associated with the inhibition of yeast-to-hypha transition, which was evaluated by a spider agar test and qRT-PCR. In addition, matrine showed a synergistic antifungal effect with FLC against resistant C. albicans, with an FICI of 0Á197, indicating that matrine could reverse the resistance of FLC against C. albicans. All these data suggested that matrine may be a candidate for the treatment of Candida-related infections.
The pharmacological actions of traditional Chinese medicines or their extracts have caused wide concern due to their easy access and low toxicity. Studies have demonstrated that some traditional Chinese medicines not only exhibited antifungal activities when used alone but also displayed synergistic antifungal effects when used in combination with FLC. It is a promising approach to overcoming antifungal drug resistance.
The antifungal activity of glucocorticoid
Glucocorticoids are the most commonly used clinical anti-inflammatory and immunosuppressive agents. The immunosuppressive mechanism is mainly to inhibit the cellular immune response, and a high dose could inhibit humoral immunity. Treating fungal infections with glucocorticoids remains controversial. Treatment with glucocorticoids increased the fungal burden in the gastrointestinal tract and the frequency of fungal translocation in rats and mice (Myerowitz 1981; Maraki et al. 1999) . However, it has also been reported that glucocorticoids could improve the prognosis of patients with severe systemic infection.
Dexamethasone
Dexamethasone, a kind of glucocorticoid, and its pharmacological functions were well studied and have drawn much attention. An early report indicated that treatment with dexamethasone (0Á01% w/v) increased the adhesion (by 17-44%) of Candida spp. to buccal epithelial cells (Ghannoum and Elteen 1987) . Adhesion to host cells is one of the virulence traits of Candida spp. (Lyon et al. 2011) . However, a recent study reported that dexamethasone exhibited a significant synergistic effect against FLCresistant C. albicans strains when combined with FLC in vitro and in vivo (Sun et al. 2017) . In this study, dexamethasone had no antifungal effect when used alone, with the MIC 80 being 128 lg ml À1 against FLC-resistant C. albicans. However, when in combination with FLC, the MIC 80 of dexamethasone was reduced to 16 lg ml À1 , and the FICI was <0Á5, indicating a strong synergism against FLC-resistant C. albicans between these two drugs (Table 1) . Further, they assessed the virulence of FLCresistant C. albicans in vivo by the G. mellonella infection model. The survival rate of larvae treated with FLC plus dexamethasone was three times higher than the PBS control group over a 4-day period. Moreover, Sun et al. also examined the function of the drug efflux pumps, the expression of drug-resistant related genes CDR1, CDR2 and MDR1 and the activity of extracellular phospholipase. Phospholipase is considered an important virulence factor of fungus, which is a major C. albicans secreted enzyme contributing to infection. The results showed that the synergistic mechanism between dexamethasone and FLC was related to inhibition of drug efflux and reduction in the virulence of FLC-resistant C. albicans. Further research on the antifungal mechanisms of dexamethasone is necessary.
Budesonide
Budesonide is also a glucocorticoid immunosuppressive agent. The study conducted by showed that budesonide in combination with FLC exhibited a significant synergistic effect against resistant C. albicans. The MIC 80 of FLC was reduced from >512 to 1 lg ml
À1
Journal of Applied Microbiology 126, 1304--1317 © 2018 The Society for Applied Microbiology when combined with budesonide against resistant C. albicans strains, and the FICI was <0Á5. Studies have shown that the synergistic mechanisms are related to induction of intracellular FLC uptake, inhibition of intracellular FLC efflux, reduction of biofilm formation, promotion of apoptosis and inhibition of extracellular phospholipase activity. The synergistic effect of budesonide in combination with FLC should also be observed against other strains. Further studies on the antifungal effects of budesonide and its mechanisms may contribute to discovering new antifungal agents.
Hydrocortisone
Glucocorticoids may also affect the growth of Aspergillus spp. Ng et al. (1994) first reported that hydrocortisone increased the growth (by 30-40%) of A. fumigatus and Aspergillus flavus in vitro. Since many cancer patients are treated with glucocorticoids and antifungal drugs simultaneously, the combined effects of these agents on Aspergillus growth have become a relevant research topic. Of interest, hydrocortisone could increase the sensitivity of Aspergillus to ITC (Ramondenc et al. 1998) . Moreover, the combination of AmB and low hydrocortisone concentrations (0Á03-0Á06 mg ml À1 ) exhibited synergy or indifference effects against the majority of Cryptococcus and Candida, with a FICI of 0Á25-1 (Hodge et al. 2015) . In addition, another study showed that treatment with hydrocortisone (0Á01% w/v) decreased the adhesion (by 16-32%) of Candida spp. to host cells (Ghannoum and Elteen 1987) . It is worthwhile to study further the antifungal activity of hydrocortisone and its antifungal mechanisms. It has been shown that glucocorticoids could increase the growth of some filamentous fungi and the adhesion of Candida spp. to host cells. Admittedly, the studies have demonstrated that glucocorticoids have a positive effect on the treatment of severe fungal infections in clinical practice. Perhaps it contributes not only to their anti-inflammatory properties but also to the synergistic antifungal effects with antifungals. Moreover, further studies are required to explore the antifungal mechanism of glucocorticoids, which may contribute to discovering new FLC sensitizers to reverse the azole resistance of C. albicans.
Conclusion
Invasive fungal disease is associated with high mortality and is a major challenge for medicine. There is an urgent need to discover new antifungal agents due to the limited available antifungal agents and the emergence of drug resistance. However, developing new antifungal agents is a long endeavour that needs time and effort. In addition to the development of new antifungals, drug combinations may be a promising option for the treatment of fungal infections infected by resistant isolates. In recent years, efforts have been made to find non-antifungal agents exhibiting synergistic effects with antifungals.
This review provides an overview of the research so far undertaken on immunosuppressant agents as potential antifungal agents and as rational adjuvants for enhancing the efficacy of conventional antifungal drugs and preventing the emergence of drug-resistant fungi. Interestingly, some of the immunosuppressive agents described above have been studied widely and demonstrated antifungal activity, especially when they were used in combination with antifungal agents in vitro. It is worth mentioning that the antifungal activity of some immunosuppressive agents has also been studied in vivo and the results suggested that used alone or combined with FLC they can significantly improve the survival rate of infected animals. More studies in vivo are required to demonstrate their efficacy and safety in the treatment of fungal infections. Although it is generally believed that the use of immunosuppressive agents will reduce the immune function and is a risk of causing fungal infection, we believe that studying analogues with low immunosuppressive activity or designing new agents based on the above-mentioned antifungal targets would be promising directions for the development of novel antifungals.
